Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Suzhou Transcenta Therapeutics Co., Ltd.

Clinical trials sponsored by Suzhou Transcenta Therapeutics Co., Ltd., explained in plain language.

Now part of Transcenta Holding Limited 6628 HKEX

Biopharmaceutical company developing antibody-based therapies for cancer and other diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 1 Not yet recruiting 1 Not yet finished but already full! 2

New antibody TST001 targets Hard-to-Treat cancers in early trial

Disease control Recruiting now

This study tests a new drug called TST001, an antibody that targets a protein called Claudin18.2 found on some cancer cells. It is given alone or with chemotherapy to people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check s…

Phase: PHASE1, PHASE2 • Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 08:05 UTC